Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Bronwyn Mixter
Jan. 20 — A video for the sedative Precedex (dexmedetomidine hydrochloride injection) is false or misleading because it omits important risk information, the FDA said in a letter posted online recently.
The Jan. 14 untitled letter, sent to Hospira Inc. in Lake Forest Ill., said the Food and Drug Administration's Office of Prescription Drug Promotion (OPDP) reviewed a video posted on YouTube for Precedex. The agency said the video misbrands Precedex under the Federal Food, Drug and Cosmetic Act.
An untitled letter cites violations that don't meet the threshold of regulatory significance for a warning letter, according to the agency's regulatory procedures manual.
Precedex is indicated for the sedation of initially intubated and mechanically ventilated patients during treatment in intensive care. It also is indicated for sedation of nonintubated patients before or during surgical and other procedures.
The FDA said the prescribing information for Precedex “contains warnings and precautions regarding drug administration, hypotension, bradycardia, sinus arrest, transient hypertension, arousability, withdrawal, tolerance, tachypylaxis and hepatic impairment.”
The FDA said the video contains several efficacy claims for Precedex but fails to include any risk information.
“By omitting the risks associated with Precedex, the video fails to provide material information about the consequences that may result from the use of the drug and creates a misleading impression about the drug's safety,” the letter said.
The agency also said the video “makes representations about the use of Precedex for intensive care unit sedation, but it is misleading because it fails to communicate material information regarding the FDA-approved indication for Precedex.”
The FDA also said the company didn't submit a copy of the video to the agency as required.
The FDA asked Hospira to stop using the video and submit a response to the letter.
“The violations discussed in this letter do not necessarily constitute an exhaustive list,” the agency said. “It is your responsibility to ensure that your promotional materials for Precedex comply with each applicable requirement of the FD&C Act and FDA implementing regulations.”
The letter was signed by Jessica M. Fox, an OPDP regulatory review officer. It also was signed by Samuel M. Skariah, an OPDP team leader.
The YouTube video has been removed. The company couldn't be reached for comment on the letter.
Hospira is part of New York-based Pfizer Inc.
To contact the reporter on this story: Bronwyn Mixter in Washington at email@example.com
To contact the editor responsible for this story: Lee Barnes at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)